C. difficile Infection with Reduced Fidaxomicin Antibiotic Susceptibility May Develop Among Hospitalized Patients

In a cohort study at a VA hospital, 5.6% of patients who received fidaxomicin had C. difficile stool isolates with reduced fidaxomicin susceptibility, some occurring after treatment.

Despite concerns about development of reduced susceptibility to fidaxomicin in patients receiving this antibiotic for Clostridioides difficile infection (CDI), the clinical implications are unclear.

Researchers at the Cleveland Veterans Affairs Medical Center analyzed stool samples from a cohort of 122 patients who had received fidaxomicin for CDI. Among these, clinical failure occurred in 7% and recurrent disease occurred in 13%. Stool samples were cultured for toxigenic C. difficile, susceptibility testing was performed, and isolates with reduced fidaxomicin susceptibility were analyzed with whole-genome sequencing.

Isolates of C. difficile were available from 108 fidaxomicin recipients. Reduced fidaxomicin susceptibility (defined as minimu…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

C. difficile Infection with Reduced Fidaxomicin Antibiotic Susceptibility May Develop Among Hospitalized Patients

Topics

Reviewing Author